SpringWorks Therapeutics Inc

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. It focuses on developing drugs for underserved patient populations suffering from devastating rare diseases and cancer. Its pipeline include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SpringWorks reports robust Q1 revenue, poised for patient-centric growth

SpringWorks Therapeutics demonstrated strong financial performance and market acceptance for OGSIVEO in Q1 2024.
The company's focus on patient-centric care and pipeline advancement positions them well for future growth and innovation.
While facing challenges in market competition and regulatory landscape, SpringWorks has opportunities for expansion and diversification.

SpringWorks reports robust Q2 earnings, focuses on expanding treatments

SpringWorks Therapeutics delivered strong financial performance in Q2 2024, driven by $40.2 million in net product revenue for OGSIVEO.
The company's focus on expanding OGSIVEO reach, advancing mirdametinib, and developing its emerging portfolio underscores its commitment to innovation.
While facing challenges such as rising operating expenses, SpringWorks remains well-positioned with a healthy cash reserve to pursue growth opportunities.
Strategically navigating challenges and capitalizing on opportunities will be crucial for SpringWorks to sustain its momentum and drive future success.

SpringWorks Therapeutics reports robust Q3 performance and eyes growth opportunities

SpringWorks Therapeutics demonstrates strong financial performance, a solid balance sheet, and positive market reception for their products. While regulatory hurdles exist, opportunities for growth through new approvals and expanded patient populations present promising prospects for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

– Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key Secondary Endpoints –

SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

STAMFORD, Conn., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Wednesday, August 10th at 10:55 a.m. ET.

SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference

STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company's Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. (“AbbVie”) until his retirement last year, brings over 30 years of experience in global commercial strategy and operations.

SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of SpringWorks Therapeutics, Inc. ("Springworks" or "the Company") (NASDAQ: SWTX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in SpringWorks Therapeutics, Inc. with Losses to Contact the Firm

HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. As per a survey of U.S. oncologists treating patients with desmoid tumors, roughly 80%.

SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch

-- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA's Real-Time Oncology Review (RTOR) Program, Expected in Second Half of 2022 -- -- New Phase 2 Study Announced to Evaluate Nirogacestat in Patients with Ovarian Granulosa Cell Tumors --

SpringWorks Therapeutics to Present Progress Across the Company's Targeted Oncology Portfolio at Virtual R&D Day

STAMFORD, Conn., June 09, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 15th at 8:40 a.m. PT / 11:40 a.m. ET.

SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

SpringWorks Therapeutics Inc. (NASDAQ: SWTX) stock jumped 20% after the clinical-stage company focusing on life-changing treatment for cancer, and rare diseases announced encouraging results from its DeFi study. The trial was a placebo-controlled, double-blind third phase study assessing the safety, tolerability, and efficacy of the company's experimental oral gamma-secretase inhibitor, Nirogacestat, in the treatment of […] The post Here is why SpringWorks Therapeutics jumped 20% appeared first on Invezz.

Here is why SpringWorks Therapeutics jumped 20%

Arcellx

Iovance Biotherapeutics

Mirati Therapeutics

Zymeworks Inc

The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week's American Society of Clinical Oncology annual meeting.

Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting

- Initial Data to be Presented from GSK-Sponsored Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose BLENREP in Patients with Relapsed or Refractory Multiple Myeloma -

SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting

SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

SpringWorks Therapeutics Inc (NASDAQ: SWTX) has announced positive topline results from the DeFi Phase 3 trial evaluating nirogacestat in adult patients with progressing desmoid tumors. Desmoid tumors are noncancerous growths occurring in the connective tissue, most often in the abdomen, arms.

Why SpringWorks Shares Are Soaring Today Premarket

Shares of SpringWorks Therapeutics Inc. SWTX, +2.18% were up 14.9% in premarket trading on Tuesday after the company said a late-stage clinical trial evaluating its treatment for patients with progressing desmoid tumors met its primary endpoint. A desmoid tumor is a rare disease.

SpringWorks shares jump 14%; company plans to seek FDA approval for desmoid tumor therapy this year

STAMFORD, Conn., May 16, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it will host a virtual R&D Day for investors and analysts on Friday, June 10, 2022 at 10:00 am ET. The program will include presentations by members of the SpringWorks executive leadership team as well as external thought leaders in the Company's core development areas. A Q&A session will follow the presentations.

SpringWorks Therapeutics to Host Virtual R&D Day on June 10, 2022

– Activities to Enable the Topline Analysis from Phase 3 DeFi Trial Underway with Data Expected in the Second Quarter –

SpringWorks Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Data from Phase 3 trial for Nirogacestat in treating desmoid tumors and Phase 2 combination trial with anti-BCMA antibody Blenrep in relapsed/refractory multiple myeloma is expected in mid-year. The company has multiple partnerships (including with Pfizer, GlaxoSmithKline, Janssen, Seattle Biosciences, Allogene, etc.) to combine Nirogacestat with their anti-BCMA therapies.

SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases

-- Collaboration Represents SpringWorks' Eighth Clinical Collaboration and Highlights Continued Execution on Strategy to Advance Nirogacestat in Combination with BCMA Therapies -- -- Collaboration Represents SpringWorks' Eighth Clinical Collaboration and Highlights Continued Execution on Strategy to Advance Nirogacestat in Combination with BCMA Therapies --

SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma

Blueprint Medicines

IVERIC bio Inc

Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many other drugs and therapies on the back burner.

Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks

– Topline Analysis from Phase 3 DeFi Trial Expected to be Triggered in the First Quarter of 2022; Topline Data Expected to be Reported During the First Half of 2022 –

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights

STAMFORD, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 am ET.

SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Results from the phase 3 DeFi study using Nirogacestat as a monotherapy for patients with desmoid tumors are expected to be released end of 2021 or early 2022. Nirogacestat is being explored in 7 combinations trials for the treatment of patients with multiple myeloma.

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

AbbVie

SpringWorks Therapeutics Inc (NASDAQ: SWTX) entered into a clinical trial collaboration agreement with AbbVie Inc (NYSE: ABBV) to evaluate SpringWorks' nirogacestat combination with ABBV-383 in relapsed or refractory multiple myeloma. Gamma secretase inhibition helps prevent the cleavage and shedding of BCMA from the surface of myeloma cells.

AbbVie, SpringWorks Join Forces To Conduct Multiple Myeloma Combo Therapy Trial

– Seventh Clinical Collaboration Represents Continued Execution on Strategy to Advance Nirogacestat in Combination with BCMA Therapies –

SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma

STAMFORD, Conn., Dec. 06, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in a Phase 1b/2 trial evaluating nirogacestat, SpringWorks' investigational gamma secretase inhibitor (GSI), in combination with elranatamab (PF-06863135) Pfizer's investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, in patients with relapsed or refractory multiple myeloma.

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

STAMFORD, Conn., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has achieved full enrollment in its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with NF1-associated plexiform neurofibromas (NF1-PN). The study enrolled over 50 adults and over 50 pediatric patients with NF1-PN. SpringWorks expects to provide an update on anticipated ReNeu trial timelines and milestones at an upcoming company-sponsored R&D Day.

SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas

News for SpringWorks Therapeutics Inc Stock (SWTX)